How are regulatory changes affecting early stage R&D in China?

December 6, 2016 Christoph Graener

Darren Ji, former VP and global head of Asia and emerging markets at Roche, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about current trends disrupting the pharma sector in China.
Darren Ji took part in a panel at BIO-Europe® 2016 focused on changes in the Chinese pharma industry. He discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes for early stage R&D in the region.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Darren Ji – Former VP, Global Head, Asia and Emerging Markets, Partnering, Roche

Previous Article
Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos
Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos

Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm, talks about how the comp...

Next Article
Digital health brings game-changing innovation
Digital health brings game-changing innovation

As will be evident at the Digital Medicine Showcase in San Francisco, digital health may become the biggest...